MX9701328A - Metodos de reduccion de la cicatrizacion en la curacion de heridas. - Google Patents

Metodos de reduccion de la cicatrizacion en la curacion de heridas.

Info

Publication number
MX9701328A
MX9701328A MX9701328A MX9701328A MX9701328A MX 9701328 A MX9701328 A MX 9701328A MX 9701328 A MX9701328 A MX 9701328A MX 9701328 A MX9701328 A MX 9701328A MX 9701328 A MX9701328 A MX 9701328A
Authority
MX
Mexico
Prior art keywords
methods
wound healing
reducing scarring
scarring
reducing
Prior art date
Application number
MX9701328A
Other languages
English (en)
Inventor
George Joseph Cullinan
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX9701328A publication Critical patent/MX9701328A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Silicates, Zeolites, And Molecular Sieves (AREA)
  • Eye Examination Apparatus (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicinal Preparation (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un método de inhibicion de la cicatrizacion que comprende administrar a un ser humano en necesidad del mismo, una cantidad efectiva de un compuesto que tiene la formula (I) en donde R1 y R3 son independientemente hidrogeno, -CH3, (a) o (b), en donde Ar es fenilo opcionalmente sustituido; R2 se selecciona del grupo que consiste de pirrolidina, hexametilenimino y piperidino; o una sal de solvato farmaceuticamente aceptable del mismo.
MX9701328A 1994-08-22 1995-08-21 Metodos de reduccion de la cicatrizacion en la curacion de heridas. MX9701328A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/293,851 US5550151A (en) 1994-08-22 1994-08-22 Methods of reducing scarring in wound healing
PCT/US1995/010650 WO1996005826A1 (en) 1994-08-22 1995-08-21 Methods of reducing scarring in wound healing

Publications (1)

Publication Number Publication Date
MX9701328A true MX9701328A (es) 1997-05-31

Family

ID=23130857

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9701328A MX9701328A (es) 1994-08-22 1995-08-21 Metodos de reduccion de la cicatrizacion en la curacion de heridas.

Country Status (14)

Country Link
US (1) US5550151A (es)
EP (1) EP0772438B1 (es)
JP (1) JPH10504823A (es)
AT (1) ATE179890T1 (es)
AU (1) AU3411195A (es)
CA (1) CA2198011A1 (es)
DE (1) DE69509657T2 (es)
DK (1) DK0772438T3 (es)
ES (1) ES2131331T3 (es)
GR (1) GR3030255T3 (es)
IL (1) IL115023A0 (es)
MX (1) MX9701328A (es)
WO (1) WO1996005826A1 (es)
ZA (1) ZA956995B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4688046B2 (ja) * 2004-11-05 2011-05-25 株式会社ポーラファルマ 肥厚性瘢痕動物モデル

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US4380635A (en) * 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
US5075321A (en) * 1987-03-24 1991-12-24 University Of Pennsylvania Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes
US5395842A (en) * 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
JP3157882B2 (ja) * 1991-11-15 2001-04-16 帝国臓器製薬株式会社 新規なベンゾチオフエン誘導体

Also Published As

Publication number Publication date
JPH10504823A (ja) 1998-05-12
EP0772438B1 (en) 1999-05-12
IL115023A0 (en) 1995-12-08
GR3030255T3 (en) 1999-08-31
DE69509657T2 (de) 1999-09-30
AU3411195A (en) 1996-03-14
DK0772438T3 (da) 1999-11-01
EP0772438A1 (en) 1997-05-14
DE69509657D1 (de) 1999-06-17
CA2198011A1 (en) 1996-02-29
WO1996005826A1 (en) 1996-02-29
EP0772438A4 (en) 1997-09-03
ZA956995B (en) 1997-02-21
US5550151A (en) 1996-08-27
ATE179890T1 (de) 1999-05-15
ES2131331T3 (es) 1999-07-16

Similar Documents

Publication Publication Date Title
MX9701329A (es) Metodos para la inhibicion de la replicacion viral.
MX9701325A (es) Metodos para inhibir la mucositis ulcerativa.
AU7578794A (en) Methods for inhibiting endometriosis
MX9701360A (es) Metodos para la inhibicion de la desmielinizacion y las enfermedades de la dismielinizacion.
AU7583494A (en) Methods of inhibiting uterine fibrosis
UA27910C2 (uk) Засіб для підвищення експресії тромбомодуліну та підвищення активації протеїну с
MX9701334A (es) Metodos para inhibir la degeneracion de protesis oseas.
MX9709466A (es) Medicamento para inhibir el melanoma.
EA199700136A1 (ru) Способы ингибирования экзогенных эстрогенов
MX9702148A (es) Metodos para inhibir la mitosis endometrial.
MX9701333A (es) Metodos para inhibir el daño neuronal.
MX9701327A (es) Metodos para inhibir el cancer endometrial.
MX9701332A (es) Metodos para curar y reparar fracturas oseas.
MX9701328A (es) Metodos de reduccion de la cicatrizacion en la curacion de heridas.
MX9701359A (es) Metodos para la inhibicion de la hiperplasia endometrial primaria.
MX9701331A (es) Metodos para mantener los dientes y los huesos bucales.
MX9705940A (es) Metodos y composiciones para inhibir los efectos de la interleucina 6.
MX9705215A (es) Uso de 2-fenil-3-aroilbenzotiofenos para inhibir los efectos de la hormona del crecimiento.
MX9709536A (es) Metodo para reducir el factor de transcripcion bef-1.
MX9702861A (es) Metodo para inhibir las condiciones asociadas con la bradicinina.
MX9709651A (es) Metodos para modulacion del factor de transcripcion nf-kb.
MX9706072A (es) Metodos de inhibicion de la adhesion celula-celula.
MX9705697A (es) Metodos para reducir los niveles de calcio del suero.
MX9702853A (es) Metodos para inhibir condiciones asociadas con el neuropeptido "y".
MX9706520A (es) Metodos para inhibir el cancer de ovario.